FDA Reviewing Fewer Generic Applications and Tentative Approvals Take Longer

The FDA’s latest quarterly snapshot of the agency’s GDUFA II performance shows fewer abbreviated new drug applications (ANDAs) under review than for the same time last year and that the agency is taking much longer to issue tentative approvals.

To View This Article:

Login

Subscribe To FDAnews

Upcoming Events

MAGI@home Clinical Research Conference 2024

Featured Products

• From QSR to QMSR: Meeting FDA’s New Requirements" width="" height="" />

From QSR to QMSR: Meeting FDA’s New Requirements

Laboratory Developed Tests" width="" height="" />

FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule